256 related articles for article (PubMed ID: 34169578)
1. The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?
Damiani G; Pacifico A; Pelloni F; Iorizzo M
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e645-e647. PubMed ID: 34169578
[No Abstract] [Full Text] [Related]
2. Reply to 'The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?' by Damiani G et al.
Avallone G; Giordano S; Astrua C; Merli M; Senetta R; Conforti C; Ribero S; Marzano AV; Quaglino P
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e433-e435. PubMed ID: 35067994
[No Abstract] [Full Text] [Related]
3. Autoimmune bullous disorder flares following severe acute respiratory syndrome coronavirus 2 vaccination: a case series.
Rasner CJ; Schultz B; Bohjanen K; Pearson DR
J Med Case Rep; 2023 Sep; 17(1):408. PubMed ID: 37749657
[TBL] [Abstract][Full Text] [Related]
4. Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid.
Solimani F; Mesas-Fernández A; Bodner E; Carevic-Neri M; Hasheminasab M; Jakovljevicova T; Philipp A; Nast A; Worm M; Hilke FJ; Meier K; Ghoreschi K
J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):e695-e697. PubMed ID: 36786360
[No Abstract] [Full Text] [Related]
5. Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine.
Agharbi FZ; Eljazouly M; Basri G; Faik M; Benkirane A; Albouzidi A; Chiheb S
Ann Dermatol Venereol; 2022 Mar; 149(1):56-57. PubMed ID: 34686374
[No Abstract] [Full Text] [Related]
6. COVID-19 and autoimmune bullous diseases: Lessons learned.
Kasperkiewicz M; Woodley DT
Autoimmun Rev; 2023 Apr; 22(4):103286. PubMed ID: 36738951
[TBL] [Abstract][Full Text] [Related]
7. Bullous pemphigoid triggered by COVID-19 vaccine: Rapid resolution with corticosteroid therapy.
Dell'Antonia M; Anedda S; Usai F; Atzori L; Ferreli C
Dermatol Ther; 2022 Jan; 35(1):e15208. PubMed ID: 34786801
[No Abstract] [Full Text] [Related]
8. COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation.
Kasperkiewicz M; Strong R; Mead K; Yale M; Zillikens D; Woodley DT; Recke A
Br J Dermatol; 2022 Apr; 186(4):737-739. PubMed ID: 34842282
[No Abstract] [Full Text] [Related]
9. Bullous pemphigoid and COVID-19 vaccine.
Pérez-López I; Moyano-Bueno D; Ruiz-Villaverde R
Med Clin (Barc); 2021 Nov; 157(10):e333-e334. PubMed ID: 34119340
[No Abstract] [Full Text] [Related]
10. A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine.
Young J; Mercieca L; Ceci M; Pisani D; Betts A; Boffa MJ
J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e13-e16. PubMed ID: 34547137
[No Abstract] [Full Text] [Related]
11. Autoimmune skin disorders and SARS-CoV-2 vaccination - a meta-analysis.
Hinterseher J; Hertl M; Didona D
J Dtsch Dermatol Ges; 2023 Aug; 21(8):853-861. PubMed ID: 37218538
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 pandemic and autoimmune bullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation.
Kasperkiewicz M; Yale M; Strong R; Zillikens D; Woodley DT; Recke A
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e418-e421. PubMed ID: 33724560
[No Abstract] [Full Text] [Related]
13. A case of acquired hemophilia A and bullous pemphigoid following SARS-CoV-2 mRNA vaccination.
Fu PA; Chen CW; Hsu YT; Wei KC; Lin PC; Chen TY
J Formos Med Assoc; 2022 Sep; 121(9):1872-1876. PubMed ID: 35321820
[TBL] [Abstract][Full Text] [Related]
14. Incident bullous pemphigoid in a psoriatic patient following mRNA-1273 SARS-CoV-2 vaccination.
Hung WK; Chi CC
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e407-e409. PubMed ID: 35073431
[No Abstract] [Full Text] [Related]
15. Absolving COVID-19 Vaccination of Autoimmune Bullous Disease Onset.
Russo R; Gasparini G; Cozzani E; D'Agostino F; Parodi A
Front Immunol; 2022; 13():834316. PubMed ID: 35251024
[No Abstract] [Full Text] [Related]
16. Evaluation of the Status of Patients with Autoimmune Bullous Diseases (Pemphigus and Bullous Pemphigoids) in Dermatology Clinics of Mashhad University of Medical Sciences During the COVID-19 Pandemic Using Telemedicine.
Mehri Z; Nahidi Y; Ramezani B; Torabi S
Telemed J E Health; 2024 Jun; 30(6):e1742-e1746. PubMed ID: 38416427
[No Abstract] [Full Text] [Related]
17. Reply to "New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin".
Maronese CA; Di Zenzo G; Genovese G; Barei F; Monestier A; Pira A; Moltrasio C; Marzano AV
Dermatol Ther; 2022 Jun; 35(6):e15496. PubMed ID: 35388592
[No Abstract] [Full Text] [Related]
18. Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation.
Akoglu G
Dermatol Ther; 2022 May; 35(5):e15396. PubMed ID: 35187768
[TBL] [Abstract][Full Text] [Related]
19. The impact of COVID-19 pandemic on the number of first diagnosis and follow-up visits of patients affected by pemphigus, bullous pemphigoid, scleroderma, psoriasis and vitiligo: A single-centre experience.
Moro F; Mariotti F; Pira A; Sobrino L; Pallotta S; Panebianco A; Di Zenzo G
J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e453-e455. PubMed ID: 38400642
[No Abstract] [Full Text] [Related]
20. Oral mucous membrane pemphigoid after SARS-CoV-2 vaccination.
Calabria E; Antonelli A; Lavecchia A; Giudice A
Oral Dis; 2024 Mar; 30(2):782-783. PubMed ID: 36516333
[No Abstract] [Full Text] [Related]
[Next] [New Search]
